vs
Side-by-side financial comparison of Getty Images Holdings, Inc. (GETY) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Getty Images Holdings, Inc. is the larger business by last-quarter revenue ($282.3M vs $177.4M, roughly 1.6× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -32.2%, a 33.8% gap on every dollar of revenue. On growth, Getty Images Holdings, Inc. posted the faster year-over-year revenue change (14.1% vs 5.0%). Over the past eight quarters, Getty Images Holdings, Inc.'s revenue compounded faster (12.7% CAGR vs -0.2%).
Getty Images Holdings, Inc. is a visual media company and supplier of stock images, editorial photography, video, and music for businesses and consumers, with a library of over 477 million assets. It targets three markets—creative professionals, the media, and corporate.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GETY vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $282.3M | $177.4M |
| Net Profit | $-90.9M | $2.9M |
| Gross Margin | 74.8% | — |
| Operating Margin | -8.5% | 3.9% |
| Net Margin | -32.2% | 1.6% |
| Revenue YoY | 14.1% | 5.0% |
| Net Profit YoY | -467.6% | — |
| EPS (diluted) | $-0.22 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $282.3M | $196.9M | ||
| Q3 25 | $240.0M | $179.5M | ||
| Q2 25 | $234.9M | $181.1M | ||
| Q1 25 | $224.1M | $168.9M | ||
| Q4 24 | $247.3M | $187.3M | ||
| Q3 24 | $240.5M | $168.6M | ||
| Q2 24 | $229.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-90.9M | — | ||
| Q3 25 | $21.6M | $5.4M | ||
| Q2 25 | $-34.4M | $-4.8M | ||
| Q1 25 | $-102.6M | $4.8M | ||
| Q4 24 | $24.7M | — | ||
| Q3 24 | $-2.5M | $-143.5M | ||
| Q2 24 | $3.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 74.8% | 79.5% | ||
| Q3 25 | 73.2% | 80.9% | ||
| Q2 25 | 72.1% | 77.4% | ||
| Q1 25 | 73.1% | 79.7% | ||
| Q4 24 | 73.5% | 78.7% | ||
| Q3 24 | 73.4% | 76.9% | ||
| Q2 24 | 72.5% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -8.5% | 1.2% | ||
| Q3 25 | 18.8% | 3.5% | ||
| Q2 25 | 15.1% | 4.7% | ||
| Q1 25 | 12.2% | 1.2% | ||
| Q4 24 | 14.5% | 13.2% | ||
| Q3 24 | 23.9% | -82.8% | ||
| Q2 24 | 20.3% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -32.2% | — | ||
| Q3 25 | 9.0% | 3.0% | ||
| Q2 25 | -14.6% | -2.7% | ||
| Q1 25 | -45.8% | 2.8% | ||
| Q4 24 | 10.0% | — | ||
| Q3 24 | -1.1% | -85.1% | ||
| Q2 24 | 1.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.22 | $0.05 | ||
| Q3 25 | $0.05 | $0.12 | ||
| Q2 25 | $-0.08 | $-0.11 | ||
| Q1 25 | $-0.25 | $0.10 | ||
| Q4 24 | $0.07 | $0.38 | ||
| Q3 24 | $-0.01 | $-3.11 | ||
| Q2 24 | $0.01 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.2M | $144.3M |
| Total DebtLower is stronger | $1.3B | — |
| Stockholders' EquityBook value | $552.5M | $653.9M |
| Total Assets | $3.2B | $1.2B |
| Debt / EquityLower = less leverage | 2.30× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $90.2M | $238.4M | ||
| Q3 25 | $109.5M | $246.3M | ||
| Q2 25 | $110.3M | $445.9M | ||
| Q1 25 | $114.6M | $493.6M | ||
| Q4 24 | $121.2M | $484.6M | ||
| Q3 24 | $109.9M | $453.8M | ||
| Q2 24 | $121.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $372.2M | ||
| Q3 25 | $1.3B | $376.7M | ||
| Q2 25 | $1.3B | $580.5M | ||
| Q1 25 | $1.3B | $583.4M | ||
| Q4 24 | $1.3B | $585.3M | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $552.5M | $693.1M | ||
| Q3 25 | $634.6M | $727.2M | ||
| Q2 25 | $611.2M | $757.8M | ||
| Q1 25 | $593.0M | $798.5M | ||
| Q4 24 | $670.2M | $778.3M | ||
| Q3 24 | $683.4M | $749.6M | ||
| Q2 24 | $654.0M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $3.2B | $1.3B | ||
| Q3 25 | $2.6B | $1.3B | ||
| Q2 25 | $2.6B | $1.5B | ||
| Q1 25 | $2.6B | $1.6B | ||
| Q4 24 | $2.6B | $1.6B | ||
| Q3 24 | $2.6B | $1.5B | ||
| Q2 24 | $2.6B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 2.30× | 0.54× | ||
| Q3 25 | 2.11× | 0.52× | ||
| Q2 25 | 2.19× | 0.77× | ||
| Q1 25 | 2.21× | 0.73× | ||
| Q4 24 | 1.96× | 0.75× | ||
| Q3 24 | 1.97× | — | ||
| Q2 24 | 2.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.6M | — |
| Free Cash FlowOCF − Capex | $7.7M | — |
| FCF MarginFCF / Revenue | 2.7% | — |
| Capex IntensityCapex / Revenue | 4.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $20.6M | $43.7M | ||
| Q3 25 | $22.6M | $60.8M | ||
| Q2 25 | $6.5M | $12.0M | ||
| Q1 25 | $15.4M | $35.5M | ||
| Q4 24 | $39.7M | $33.1M | ||
| Q3 24 | $10.7M | $53.9M | ||
| Q2 24 | $46.4M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $7.7M | $43.5M | ||
| Q3 25 | $7.9M | $57.0M | ||
| Q2 25 | $-9.6M | $9.3M | ||
| Q1 25 | $-322.0K | $26.9M | ||
| Q4 24 | $24.6M | $31.0M | ||
| Q3 24 | $-1.8M | $49.8M | ||
| Q2 24 | $31.1M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 22.1% | ||
| Q3 25 | 3.3% | 31.7% | ||
| Q2 25 | -4.1% | 5.1% | ||
| Q1 25 | -0.1% | 15.9% | ||
| Q4 24 | 9.9% | 16.6% | ||
| Q3 24 | -0.8% | 29.6% | ||
| Q2 24 | 13.6% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | 0.1% | ||
| Q3 25 | 6.1% | 2.2% | ||
| Q2 25 | 6.9% | 1.5% | ||
| Q1 25 | 7.0% | 5.1% | ||
| Q4 24 | 6.1% | 1.1% | ||
| Q3 24 | 5.2% | 2.4% | ||
| Q2 24 | 6.7% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.05× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | 1.61× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 12.59× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GETY
| Creative | $149.0M | 53% |
| Editorial | $109.4M | 39% |
| Other | $23.9M | 8% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
